Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs McKesson Corporation — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43.11, while McKesson Corporation trades at $884 (market cap $105.14B). The key difference: McKesson Corporation pays a 0.42% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and McKesson Corporation is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| GPTY | MCK | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $995.69 |
52-Week Low | $34.73 | $659.01 |
Market Cap | — | $105.14B |
Enterprise Value | — | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $43.11, up 1.07% with a bullish technical signal supported by moving averages. The YieldMax AI & Tech Portfolio Option Income ETF demonstrates consistent weekly dividend distributions, with recent payouts ranging from $0.28-$0.37. Technical indicators show strong momentum with RSI at 83.06 suggesting potential overbought conditions, while support and resistance cluster around $42-$43 levels.
The ETF's strategy of harvesting options premiums from AI and semiconductor stocks provides high yield exposure, though the concentrated tech focus and elevated RSI levels warrant caution. Recent analysis highlights GPTY's balance of income generation and capital preservation compared to peers, but dependence on semiconductor momentum presents volatility risks.
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
